<strong>Objectives:</strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> To study the epidemiological, diagnos...<strong>Objectives:</strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> To study the epidemiological, diagnostic, therapeutic </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> prognostic aspects of gastric adenocarcinoma at the Joliot Curie Institute in Dakar. </span><b><span style="font-family:Verdana;">Materials and Methods: </span></b><span style="font-family:Verdana;">We conducted a retrospective study over </span><span style="font-family:Verdana;">a seven-year period</span><span style="font-family:Verdana;"> from January 2010 to December 2017 at the Joliot Curie Institute in Dakar. All cases of gastric adenocarcinoma proven by </span><span style="font-family:Verdana;">fibroscopy</span><span style="font-family:Verdana;"> followed by histology or proven on the histological analysis of a surgical specimen were taken into account. The parameters studied were age, risk factors, stages of the disease, treatment </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> prognosis. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> There were 54 cases of gastric adenocarcinoma </span><span style="font-family:Verdana;">over a period of</span><span style="font-family:Verdana;"> 7 years. The average age was 54.74 years with extremes of 25 and 84 years. A male predominance was noted (35/54). The main risk factors found were alcohol (5/54), tobacco (13/54), </span><i><span style="font-family:Verdana;">Helicobacter </span><span style="font-family:Verdana;">pilori</span></i><span style="font-family:Verdana;"> (4/54), gastric ulcer (12/54). Epigastralgia was the most frequent clinical manifestation. </span><span style="font-family:Verdana;">FOGD</span><span style="font-family:Verdana;"> was carried out in 77.8% of patients. Histology was obtained before surgery in 40 patients (74.1% of cases) and </span><span style="font-family:Verdana;">on</span><span style="font-family:Ve展开更多
<strong>Background:</strong><span><span><span style="font-family:""><span style="font-family:Verdana;"> Phylloid sarcomas are rare. There is not enough data...<strong>Background:</strong><span><span><span style="font-family:""><span style="font-family:Verdana;"> Phylloid sarcomas are rare. There is not enough data to codify the management. </span><b><span style="font-family:Verdana;">Objectives:</span></b><span style="font-family:Verdana;"> The objective was to study the clinical and therapeutic aspects and the fate of patients after a follow-up of at least 4 years. Thus contributing to the limited body of knowledge on these tumors. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> a retrospective analysis of the files from 2013 to 2017 was carried out and patients were followed up until 2021at Hassan II Hospital. Epidemiological, clinical and therapeutic aspects were studied. Survival was calculated using the Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> We collected 12 charts of patients treated for phyllodeal sarcoma from 2013 to 2017. The median age was 43 years. The circumstance of discovery was marked by the presence of nodule in all patients. The coupled echo-mammography examination classified the nodules, ACR 4 in 7 patients and ACR 3 in 3 and ACR 5 in 2 patients. Histological examination revealed a phylloid sarcoma in 11 patients and a borderline phylloid tumor in 1 patient. All patients had radical surgery with positive margins in 2 patients, 16.66%. One patient had revision surgery. Histological examination of the surgical specimens showed phylloid sarcoma on all specimens. All patients had adjuvant radiotherapy with doses of 50 Gy in 25 fractions of 2 Gy and a boost of 10 Gy was done in one patient. The median spread of radiotherapy was 37 days. Grade 1 and 2 skin toxicities were noted in 5 and 3 patients respectively. The median time from surgery to radiotherapy was 2.95 months. 3 patients relapsed after 13.6 months of follow-up. The recurrence-free survival at 1 and 3 years was 83% and 75% respectively. Overall survival at 3 and 5 y展开更多
文摘<strong>Objectives:</strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;"> To study the epidemiological, diagnostic, therapeutic </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> prognostic aspects of gastric adenocarcinoma at the Joliot Curie Institute in Dakar. </span><b><span style="font-family:Verdana;">Materials and Methods: </span></b><span style="font-family:Verdana;">We conducted a retrospective study over </span><span style="font-family:Verdana;">a seven-year period</span><span style="font-family:Verdana;"> from January 2010 to December 2017 at the Joliot Curie Institute in Dakar. All cases of gastric adenocarcinoma proven by </span><span style="font-family:Verdana;">fibroscopy</span><span style="font-family:Verdana;"> followed by histology or proven on the histological analysis of a surgical specimen were taken into account. The parameters studied were age, risk factors, stages of the disease, treatment </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> prognosis. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> There were 54 cases of gastric adenocarcinoma </span><span style="font-family:Verdana;">over a period of</span><span style="font-family:Verdana;"> 7 years. The average age was 54.74 years with extremes of 25 and 84 years. A male predominance was noted (35/54). The main risk factors found were alcohol (5/54), tobacco (13/54), </span><i><span style="font-family:Verdana;">Helicobacter </span><span style="font-family:Verdana;">pilori</span></i><span style="font-family:Verdana;"> (4/54), gastric ulcer (12/54). Epigastralgia was the most frequent clinical manifestation. </span><span style="font-family:Verdana;">FOGD</span><span style="font-family:Verdana;"> was carried out in 77.8% of patients. Histology was obtained before surgery in 40 patients (74.1% of cases) and </span><span style="font-family:Verdana;">on</span><span style="font-family:Ve
文摘<strong>Background:</strong><span><span><span style="font-family:""><span style="font-family:Verdana;"> Phylloid sarcomas are rare. There is not enough data to codify the management. </span><b><span style="font-family:Verdana;">Objectives:</span></b><span style="font-family:Verdana;"> The objective was to study the clinical and therapeutic aspects and the fate of patients after a follow-up of at least 4 years. Thus contributing to the limited body of knowledge on these tumors. </span><b><span style="font-family:Verdana;">Methods:</span></b><span style="font-family:Verdana;"> a retrospective analysis of the files from 2013 to 2017 was carried out and patients were followed up until 2021at Hassan II Hospital. Epidemiological, clinical and therapeutic aspects were studied. Survival was calculated using the Kaplan-Meier method. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> We collected 12 charts of patients treated for phyllodeal sarcoma from 2013 to 2017. The median age was 43 years. The circumstance of discovery was marked by the presence of nodule in all patients. The coupled echo-mammography examination classified the nodules, ACR 4 in 7 patients and ACR 3 in 3 and ACR 5 in 2 patients. Histological examination revealed a phylloid sarcoma in 11 patients and a borderline phylloid tumor in 1 patient. All patients had radical surgery with positive margins in 2 patients, 16.66%. One patient had revision surgery. Histological examination of the surgical specimens showed phylloid sarcoma on all specimens. All patients had adjuvant radiotherapy with doses of 50 Gy in 25 fractions of 2 Gy and a boost of 10 Gy was done in one patient. The median spread of radiotherapy was 37 days. Grade 1 and 2 skin toxicities were noted in 5 and 3 patients respectively. The median time from surgery to radiotherapy was 2.95 months. 3 patients relapsed after 13.6 months of follow-up. The recurrence-free survival at 1 and 3 years was 83% and 75% respectively. Overall survival at 3 and 5 y
